Abstracts Archive - Page 2588 of 2607 - ACR Meeting Abstracts

Abstract Number: 245 • 2012 ACR/ARHP Annual Meeting
Similarities of Patient Self-Report Scores From a Multidimensional Health Assessment Questionnaire (MDHAQ), Laboratory Tests, Physician Global Assessment, and Polyarticular Involvement in Patients with Osteoarthritis and Rheumatoid Arthritis
Isabel Castrejón¹, Yusuf Yazici² and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are distinct diagnoses, based on widely differing pathogenetic mechanisms and treatments. However, OA patients may experience functional disability,…
Abstract Number: 246 • 2012 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3) Is a Valid Index for Routine Care in Patients with Osteoarthritis
Alfredomaria Lurati¹, Luca Bertani¹, Daniela Bompane¹, Mariagrazia Marrazza¹, Katia Angela Re¹ and Magda Scarpellini², ¹Ospedale Fornaroli, Rheumatology Unit, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy
Background/Purpose: RAPID3 (routine assessment of patient index data) is an arithmetic composite index of three Core Data Set, patient self-report, measures: physical function (0-3 converted…
Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting
Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement – the RIM Study
Cynthia S. Crowson¹, Ann M. Reed², Molly Hein³, Abigail B. Green¹, Consuelo Lopez de Padilla⁴, Rohit Aggarwal⁵, Dana P. Ascherman⁶, Marc C. Levesque⁷ and Chester V. Oddis⁸, ¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…
Abstract Number: 208 • 2012 ACR/ARHP Annual Meeting
Outcome of Muscle Function and Disease Activity in Patients Recently Diagnosed with Polymyositis and Dermatomyositis – Preliminary Results of a 1-Year Follow-up Registry Study
Helene Alexanderson¹, Jenny Bergegård², Christina Ottosson³, Maryam Dastmalchi⁴ and Ingrid E. Lundberg⁵, ¹Dept of Neuroscience, Care Science and Society, Karolinska Institutet, Stockholm, Sweden, ²Department of Physical Therapy, Orthopedic/Rheumatology Unit, Karolinska University Hospital, Solna, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁴Department of Medicine, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Most patients with polymyositis (PM) and dermatomyositis (DM) develop sustained muscle impairment. The aim of this study was to evaluate the muscle endurance (Functional…
Abstract Number: 209 • 2012 ACR/ARHP Annual Meeting
Clinical Study of Determination of Myositis-Associated Autoantibodies in Japanese Patients with Connective Tissue Diseases except Autoimmune Myositis
Toshio Kawamoto¹, Masakazu Matsushita¹, Ken Yamaji¹, Naoto Tamura¹ and Yoshinari Takasaki², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Anti-Jo-1 antibody is detected in the sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen to which this antibody is directed is histidyl-tRNA synthase, an…
Abstract Number: 210 • 2012 ACR/ARHP Annual Meeting
An Analysis of Metabolic Syndrome in Adult Dermatomyositis with a Focus On Cardiovascular Disease
Mariana T. Moraes¹, Fernando H.C. Souza², Thiago B. M. Barros¹ and Samuel K. Shinjo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with increased cardiovascular risk. MetS has been systematically evaluated in all systemic autoimmune rheumatic…
Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review
JA Martinez-Lopez Sr.¹, J. Graña Sr.², Santiago Muñoz-Fernandez³, I. Rua-Figueroa⁴, José M. Pego-Reigosa⁵, Estíbaliz Loza Sr.⁶ and SER group for the study of systemic autoimmune diseases⁷, ¹Fundacion Jimenez Diaz, Madrid, Spain, ²Hospital Juan Canalejo, Spain, ³Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ⁶Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁷Madrid
Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…
Abstract Number: 212 • 2012 ACR/ARHP Annual Meeting
Distinctive Characteristics of Anti-Mi-2 and –p155/140 Autoantibody Production in Two Cohorts of Mexican Patients with Dermatomyositis
Monica Vazquez-Del Mercado¹, Marcelo Petri¹, Luis J. Jara-Quezada², Miguel A. Saavedra-Salinas³, Claudia Cruz-Reyes⁴, Olga-Lidia Vera-Lastra⁵, Lilia Andrade⁶, Mario Salazar-Paramo⁷, Laura Gonzalez-Lopez⁸, Jorge Gamez-Nava⁹, Rosa E. Prieto-Parra⁷, Teresita Martin Marquez¹, Jason Y.F. Chan¹⁰, Edward K.L. Chan¹¹ and Minoru Satoh¹⁰, ¹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ²Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Rheumatology, Centro Médico Nacional, México, Mexico, ⁴Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, ⁵Rheumatology, Inst Mexicano Seguro Social, Mexico City, Mexico, ⁶CMN 20 Noviembre ISS STE, Mexico, Mexico, ⁷Clinical Research Division, Instituto Mexicano Del SS, Guadalajara, Mexico, ⁸Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, ⁹Rheumatology, Centro Medico de Occidente, Guadalajara Jal, Mexico, ¹⁰Medicine, University of Florida, Gainesville, FL, ¹¹Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Various autoantibodies associated with a unique subset of polymyositis/dermatomyositis (PM/DM), including antibodies to Jo-1 and other synthetases, SRP, Mi-2, PM-Scl and others, have been…
Abstract Number: 213 • 2012 ACR/ARHP Annual Meeting
Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery
Matthias Rother¹, Egbert J. Seidel², Alexander Fischer² and Ilka Rother¹, ¹IMR Partner GmbH, Graefelfing, Germany, ²Department of Physical and Rehabilitation Medicine, Sophien- and Hufeland Clinic, Weimar, Germany
Background/Purpose: Eccentric muscle contraction causes an inflammatory reaction with pain peaking 24 to 48 hours after exercise – delayed onset of muscle soreness (DOMS). NSAIDs…
Abstract Number: 214 • 2012 ACR/ARHP Annual Meeting
Inflammatory Muscle Disease Associated Pulmonary Hypertension – Clinical Features and Survival At a National Referral Centre
Matthew Webber¹, D. Dobarro¹, Clive Handler², Christopher P. Denton³, Benjamin E. Schreiber⁴ and John G. Coghlan⁵, ¹Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom, ²Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁵National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: The association between connective tissue disease (CTD) and pulmonary hypertension (PH) is well known, especially in the scleroderma population. However, the association between inflammatory…
Abstract Number: 215 • 2012 ACR/ARHP Annual Meeting
Abnormal Videofluoroscopy Swallow Study Finding in Inflammatory Myopathy Patient with Dysphagia As Predictor of Prognosis
Hye Won Kim¹, Hwang Kim¹, Sung Hae Chang¹, Hye Jin Oh¹, Myeong Jae Yoon¹, Bong Seung Ku¹, Byeong Mo Oh² and Eun Young Lee³, ¹Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ²Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Previous reports of dysphagia in patients with inflammatory myopathy (IM) have been focused on detection, intervention and rehabilitation. However, whether dysphagia with abnormal videofluoroscopy…
Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting
Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis
Yuji Hosono¹, Ran Nakashima¹, Yoshitaka Imura², Naoichiro Yukawa³, Hajime Yoshifuji¹, Motomu Hashimoto⁴, Koichiro Ohmura⁵, Takao Fujii⁶ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…
Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting
Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis
Christine McBurney¹, Rohit Aggarwal², Kevin Gibson³, Kathleen Lindell⁴, Carl Fuhrman⁵, Diane Koontz⁶, Frank Schneider⁷, Naftali Kaminski⁴ and Chester V. Oddis⁸, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, ⁵Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Anatomic Pathology Department, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…
Abstract Number: 218 • 2012 ACR/ARHP Annual Meeting
Proteomics Study of a Phase 1b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin 2 Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis
Xiang Guo¹, Brandon W. Higgs¹, Wei Zhu², Yihong Yao¹ and Wendy White³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose: To evaluate downstream effects of an anti-IFN-α monoclonal antibody (mAb) in adult dermatomyositis (DM) and polymyositis (PM) patients using serum proteomics and gene expression…
Abstract Number: 219 • 2012 ACR/ARHP Annual Meeting
Significant Functional Improvement Using Aggressive Immunomodulatory Therapy in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Ramona Mihu¹, Roger D. Rossen², Jovan Popovich³ and Sandra L. Sessoms¹, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, ³Medicine/Rheumatology, The Methodist Hospital, Houston, TX
Background/Purpose: Pulmonary disease in patients with idiopathic inflammatory myopathies, polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM) is a major cause of morbidity. Approximately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].